Oral Insulin Research Brings New Hope for Diabetes Treatment Without Daily Injections
A new scientific review published in 2026 highlights the growing potential of oral insulin as a future alternative to insulin injections for people living with diabetes. The study, written by Rehan Haider and colleagues from University of Karachi, SBB Dewan University, Dow University of Health Sciences, and OPJS University, examines the latest progress, clinical evidence, and engineering challenges in developing insulin pills for diabetes management. The findings are important because diabetes continues to rise globally and affects more than 530 million people. For many patients with Type 1 Diabetes and advanced Type 2 Diabetes, insulin injections remain essential. However, daily injections often cause pain, needle anxiety, and treatment fatigue, making long-term adherence difficult. Researchers say oral insulin could transform diabetes care by making treatment easier, more comfortable, and potentially more physiologically similar to how the body naturally uses insulin.
A new scientific review published in 2026 highlights the growing potential of oral insulin as a future alternative to insulin injections for people living with diabetes. The study, written by Rehan Haider and colleagues from University of Karachi, SBB Dewan University, Dow University of Health Sciences, and OPJS University, examines the latest progress, clinical evidence, and engineering challenges in developing insulin pills for diabetes management. The findings are important because diabetes continues to rise globally and affects more than 530 million people. For many patients with Type 1 Diabetes and advanced Type 2 Diabetes, insulin injections remain essential. However, daily injections often cause pain, needle anxiety, and treatment fatigue, making long-term adherence difficult. Researchers say oral insulin could transform diabetes care by making treatment easier, more comfortable, and potentially more physiologically similar to how the body naturally uses insulin.
Why Oral Insulin Matters
Insulin therapy has saved millions of lives, but delivering insulin by injection is still a major barrier for many patients. Some delay treatment because of fear of needles, while others struggle with the inconvenience of multiple daily injections. Oral insulin has long been considered a “holy grail” in diabetes treatment because it could mimic the body’s natural insulin pathway. Instead of entering the bloodstream directly through injection, oral insulin first travels through the digestive system and reaches the liver through portal circulation, closer to how insulin is released from the pancreas. This pathway could improve blood sugar regulation while reducing excessive insulin exposure in other tissues.
The Main Challenge: Insulin Is Hard to Deliver by Mouth
Despite decades of research, creating an effective insulin pill remains difficult. Insulin is a protein, and proteins are easily destroyed in the stomach before they can be absorbed.
The research team explains that oral insulin faces three major biological obstacles:
-stomach acid breaks down insulin molecules,
-digestive enzymes destroy the protein,
-the intestinal wall blocks large molecules from entering the bloodstream.
Because of these barriers, scientists are developing advanced drug delivery systems that can protect insulin until it reaches the small intestine.
Promising Technologies Under Development
The review examined several emerging technologies designed to improve oral insulin absorption.
Among the most advanced are:
-enteric-coated capsules,
-nanoparticle carriers,
-mucoadhesive polymers,
-glucose-responsive smart materials.
One of the best-known candidates is ORMD-0801, developed by Oramed Pharmaceuticals. The capsule uses protective coatings and absorption enhancers to help insulin survive the digestive tract. Another candidate, Insulin Tregopil, developed by Biocon, has shown encouraging effects in controlling blood sugar after meals. However, both formulations still show limited overall effectiveness compared with injected insulin.
Clinical Results: Safe but Not Yet Strong Enough
The researchers reviewed clinical trial data and found that current oral insulin products generally reduce long-term blood sugar levels (HbA1c) by only 0.4% to 0.6%, which is lower than standard injectable insulin.
Key findings include:
-bioavailability remains very low, only 2–5%,
-effects vary widely between patients,
-hypoglycemia risk is generally low,
-mild digestive side effects are common.
The review notes that late-stage clinical trials for ORMD-0801 did not achieve statistically significant results, leading to the discontinuation of its Phase III development program. Still, researchers believe oral insulin may be useful as:
-an early intervention for type 2 diabetes,
-a supplemental therapy with injected basal insulin,
-an option for patients who avoid needles.
Nanotechnology Offers a New Path
One of the most promising breakthroughs comes from nanotechnology.
The study highlights experimental systems that use tiny engineered particles to protect insulin and improve intestinal absorption. These include:
-chitosan-based nanoparticles,
-lipid-polymer hybrid nanoparticles,
-vitamin B12-linked carriers,
-pH-responsive nanogels.
In animal studies, these systems improved insulin absorption by two to three times compared with conventional oral tablets. Some experimental formulations reduced blood glucose in diabetic rats by nearly 50% within eight hours, suggesting strong future potential. According to Rehan Haider, these technologies are still largely in preclinical stages, but they represent a major step toward practical oral insulin.
Future Engineering Strategies
The review emphasizes that oral insulin’s future depends not only on pharmacology but also on engineering innovation. Researchers identify several next-generation strategies:
-targeted ileal delivery systems,
-receptor-mediated intestinal transport,
-AI-assisted pharmacokinetic modeling,
-smart glucose-responsive polymers.
These systems aim to release insulin only when blood sugar rises, reducing the risk of dangerous hypoglycemia. Such “smart insulin” platforms could eventually provide treatment that automatically adapts to the patient’s metabolic needs.
Potential Impact for Healthcare
If oral insulin becomes clinically successful, the impact could be significant for global healthcare systems. Potential benefits include:
-improved treatment adherence,
-reduced needle-related anxiety,
-earlier insulin use in type 2 diabetes,
-better quality of life,
-lower long-term complications.
This could also reduce healthcare costs by improving blood sugar control and preventing complications such as kidney failure, blindness, and cardiovascular disease.
Author Profiles
Rehan Haider
Lead researcher from University of Karachi. His work focuses on pharmaceutical sciences, diabetes therapeutics, and drug delivery technologies.
Shabana Naz Shah
Researcher at SBB Dewan University, specializing in clinical pharmacology.
Zimmer Ahmed, Hina Abbas, and Sambreen Zameer
Researchers from Dow University of Health Sciences with expertise in biomedical research and clinical sciences.
Geetha Kumari Das
Academic from OPJS University specializing in pharmaceutical engineering.
Research Source
This article is based on the scientific paper:
“Oral Insulin Delivery: Translational Barriers, Clinical Evidence, and Emerging Engineering Strategies in Diabetes Management”
Published in International Journal of Applied and Scientific Research, 2026.
0 Komentar